Add an ACE Inhibitor or ARB as the Fourth Agent
For a patient on amlodipine 10 mg and hydrochlorothiazide 25 mg with uncontrolled hypertension, you should add an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) to complete the recommended first-line triple therapy regimen 1, 2.
Rationale for This Recommendation
The 2025 AHA/ACC hypertension guidelines explicitly state that antihypertensive drug therapy should start with a combination of an ACEi or ARB, a calcium channel blocker (CCB), and a diuretic 1, 2. Your patient currently has two of these three components:
- CCB: Amlodipine 10 mg (at maximum dose per FDA labeling 3)
- Diuretic: Hydrochlorothiazide 25 mg
The missing component is the ACEi or ARB, which provides complementary blood pressure reduction through renin-angiotensin system blockade.
Important Consideration: Optimize the Diuretic First
Before adding the third agent, strongly consider switching hydrochlorothiazide to a thiazide-like diuretic (chlorthalidone or indapamide). The guidelines specifically note that replacing thiazide-type diuretics like HCTZ with thiazide-like diuretics may offer additional BP reduction and cardiovascular protection 1, 2. This is a critical optimization step that many clinicians overlook.
If Blood Pressure Remains Uncontrolled on Triple Therapy
Should your patient's BP remain ≥130/80 mm Hg despite optimal doses of ACEi/ARB + amlodipine + thiazide-like diuretic, this constitutes resistant hypertension. At that point:
Add spironolactone 25-50 mg daily as the fourth agent (if eGFR ≥45 mL/min/1.73 m²) 1, 2. This recommendation is based on high-quality RCT evidence showing spironolactone reduces 24-hour systolic BP by 6.6-8.7 mm Hg compared to placebo in resistant hypertension, with greater efficacy than doxazosin or bisoprolol 2.
Monitoring for Spironolactone
- Check serum potassium within 1-2 weeks after initiation
- Monitor for hyperkalemia (4-40% incidence) and antiandrogenic side effects (gynecomastia, sexual dysfunction) 1, 2
- If spironolactone is not tolerated, amiloride 10-20 mg is equally effective 2
Clinical Evidence Supporting Triple Combination
Multiple studies demonstrate that the ACEi/ARB + CCB + diuretic combination achieves superior BP control compared to dual therapy. Research specifically examining olmesartan/amlodipine/hydrochlorothiazide showed BP reductions of 30-40/20-25 mm Hg with triple therapy versus 25-32/14-20 mm Hg with dual combinations 4, 5, 6. This benefit was consistent across patients with diabetes, chronic kidney disease, cardiovascular disease, obesity, and elderly populations 4, 7, 8.
Common Pitfalls to Avoid
- Don't continue HCTZ when you could use chlorthalidone or indapamide - the thiazide-like diuretics provide superior cardiovascular outcomes
- Don't add a fourth agent before optimizing the first three - ensure maximum tolerated doses of the triple combination first
- Don't screen for secondary hypertension yet - complete the first-line triple therapy optimization first, unless clinical features strongly suggest secondary causes
- Don't use ACEi + ARB together - this combination is contraindicated 9